Given the different methods of poultry production between countries and the presence of wild birds and their natural routes and behaviours, it remains difficult to eradicate Newcastle disease and bring down its currently high rates of occurrence, being still endemic in most countries in Asia, the Middle East, Africa, Central America and South America.
That is why HIPRA commissioned Avimune, an independent South African company, to conduct a study to test the efficacy of the different vaccines available on the South African market following controlled infection with a strain of Newcastle virus belonging to genotype III.
Given the results obtained in the test performed, it may be concluded that all the vaccines used during the test are able to confer protection against a strain of a genotype other than that of the vaccine.
